Abstract
Monoclonal antibodies directed against two human B cell-restricted antigens, CD19 and CD22, were conjugated to highly purified ricin A chain. These A chain immunotoxins (A-IT) were specifically cytotoxic to Daudi cells and normal human peripheral blood B cells in vitro. The concentration required for 50% inhibition of protein synthesis (IC50) in these cells ranged from 7.5 x 10-10 M to 4.2 x 10-9 M. The specific toxicities of these A-ITs for Daudi cells were augmented 2-to 6-fold in the presence of 20mM NH4Cl. These studies demonstrate that A-ITs specific for CD19 and CD22 may be useful in the clinical treatment of B cell malignancies.
Original language | English (US) |
---|---|
Pages (from-to) | 261-272 |
Number of pages | 12 |
Journal | Cancer Drug Delivery |
Volume | 3 |
Issue number | 4 |
DOIs | |
State | Published - 1986 |
ASJC Scopus subject areas
- Pharmacology
- Cancer Research